The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF. At present, there have been few systematic and detailed reviews discussing the efficacy and safety of s...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-01-01
|
| Series: | Journal of Cardiovascular Pharmacology and Therapeutics |
| Online Access: | https://doi.org/10.1177/10742484211058681 |
| _version_ | 1818025044254654464 |
|---|---|
| author | Rui Zhang MD, PhD Xiaotong Sun PhD Ya Li MD, PhD Wenzheng He MM Hongguang Zhu MD, PhD Baoshan Liu MD, PhD Aiyuan Zhang MD, PhD |
| author_facet | Rui Zhang MD, PhD Xiaotong Sun PhD Ya Li MD, PhD Wenzheng He MM Hongguang Zhu MD, PhD Baoshan Liu MD, PhD Aiyuan Zhang MD, PhD |
| author_sort | Rui Zhang MD, PhD |
| collection | DOAJ |
| description | Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF. At present, there have been few systematic and detailed reviews discussing the efficacy and safety of sacubitril/valsartan in HF. In this review, we first introduced the pharmacological mechanisms of sacubitril/valsartan, including the reduction in the degradation of natriuretic peptides in the natriuretic peptide system and inhibition of the renin-angiotensin system. Then, we summarized the efficacy of sacubitril/valsartan in HF patients with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) including the reduction in risks of mortality and hospitalization, reversal of cardiac remodeling, regulation of biomarkers of HF, improvement of the quality of life, antiarrhythmia, improving renal dysfunction and regulation of metabolism. Finally, we discussed the safety and tolerability of sacubitril/valsartan in the treatment of HFrEF or HFpEF. Compared with ACEIs/ARBs or placebo, sacubitril/valsartan showed good safety and tolerability, although the risk of hypotension might be high. In conclusion, the overwhelming majority of studies show that sacubitril/valsartan is effective and safe in the treatment of HFrEF patients but that it has little benefit in HFpEF patients. Sacubitril/valsartan will probably be a promising anti-HF drug in the near future. |
| first_indexed | 2024-12-10T04:09:51Z |
| format | Article |
| id | doaj.art-dd5a6a33e7ea44a8b228e0f9866792b9 |
| institution | Directory Open Access Journal |
| issn | 1940-4034 |
| language | English |
| last_indexed | 2024-12-10T04:09:51Z |
| publishDate | 2022-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Cardiovascular Pharmacology and Therapeutics |
| spelling | doaj.art-dd5a6a33e7ea44a8b228e0f9866792b92022-12-22T02:02:46ZengSAGE PublishingJournal of Cardiovascular Pharmacology and Therapeutics1940-40342022-01-012710.1177/10742484211058681The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A ReviewRui Zhang MD, PhD0Xiaotong Sun PhD1Ya Li MD, PhD2Wenzheng He MM3Hongguang Zhu MD, PhD4Baoshan Liu MD, PhD5Aiyuan Zhang MD, PhD6 Cardiac Rehabilitation Centre, , Weifang, China Shandong Provincial Medicine and Health Key Laboratory of Clinical Anesthesia, Department of Anesthesiology, Weifang Medical University, Weifang, China Department of Cardiology, Shanghai General Hospital, School of Medicine, , Hongkou District, Shanghai, China Intensive Care Unit, , Weifang, China Dental Department, , Weifang, China Cardiac Rehabilitation Centre, , Weifang, China Cardiac Rehabilitation Centre, , Weifang, ChinaHeart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the treatment of HF. At present, there have been few systematic and detailed reviews discussing the efficacy and safety of sacubitril/valsartan in HF. In this review, we first introduced the pharmacological mechanisms of sacubitril/valsartan, including the reduction in the degradation of natriuretic peptides in the natriuretic peptide system and inhibition of the renin-angiotensin system. Then, we summarized the efficacy of sacubitril/valsartan in HF patients with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF) including the reduction in risks of mortality and hospitalization, reversal of cardiac remodeling, regulation of biomarkers of HF, improvement of the quality of life, antiarrhythmia, improving renal dysfunction and regulation of metabolism. Finally, we discussed the safety and tolerability of sacubitril/valsartan in the treatment of HFrEF or HFpEF. Compared with ACEIs/ARBs or placebo, sacubitril/valsartan showed good safety and tolerability, although the risk of hypotension might be high. In conclusion, the overwhelming majority of studies show that sacubitril/valsartan is effective and safe in the treatment of HFrEF patients but that it has little benefit in HFpEF patients. Sacubitril/valsartan will probably be a promising anti-HF drug in the near future.https://doi.org/10.1177/10742484211058681 |
| spellingShingle | Rui Zhang MD, PhD Xiaotong Sun PhD Ya Li MD, PhD Wenzheng He MM Hongguang Zhu MD, PhD Baoshan Liu MD, PhD Aiyuan Zhang MD, PhD The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review Journal of Cardiovascular Pharmacology and Therapeutics |
| title | The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review |
| title_full | The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review |
| title_fullStr | The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review |
| title_full_unstemmed | The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review |
| title_short | The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review |
| title_sort | efficacy and safety of sacubitril valsartan in heart failure patients a review |
| url | https://doi.org/10.1177/10742484211058681 |
| work_keys_str_mv | AT ruizhangmdphd theefficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT xiaotongsunphd theefficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT yalimdphd theefficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT wenzhenghemm theefficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT hongguangzhumdphd theefficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT baoshanliumdphd theefficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT aiyuanzhangmdphd theefficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT ruizhangmdphd efficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT xiaotongsunphd efficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT yalimdphd efficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT wenzhenghemm efficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT hongguangzhumdphd efficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT baoshanliumdphd efficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview AT aiyuanzhangmdphd efficacyandsafetyofsacubitrilvalsartaninheartfailurepatientsareview |